About eGenesis
eGenesis is a company based in Cambridge (United States) founded in 2015 by George M Church.. eGenesis has raised $481.42 million across 6 funding rounds from investors including Bayer, ARE and DaVita. The company has 94 employees as of December 31, 2022. eGenesis has completed 1 acquisition, including ICBiotec. eGenesis offers products and services including EGEN Platform and HuCo Organs. eGenesis operates in a competitive market with competitors including Beam Therapeutics, Korro Bio, Metagenomi, Prime Medicine and Scribe Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 94 as on 31 Dec, 2022
- Founders George M Church
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Egenesis, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of eGenesis
eGenesis offers a comprehensive portfolio of products and services, including EGEN Platform and HuCo Organs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tool for engineering organs to overcome xenotransplantation barriers.
Genetically modified porcine organs for human compatibility.
Unlock access to complete
Unlock access to complete
Funding Insights of eGenesis
eGenesis has successfully raised a total of $481.42M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $191 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series D — $191.0M
-
First Round
First Round
(22 Aug 2016)
- Investors Count 27
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Series D - eGenesis | Valuation | Lux Capital | |
| Feb, 2024 | Amount | Series C - eGenesis | Valuation |
investors |
|
| Mar, 2021 | Amount | Series C - eGenesis | Valuation | Farallon Capital Management , Polaris Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in eGenesis
eGenesis has secured backing from 27 investors, including institutional and venture fund investors. Prominent investors backing the company include Bayer, ARE and DaVita. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by eGenesis
eGenesis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ICBiotec. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of gene editing platform for the development of human-compatible organs, tissues and cells
|
1998 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - eGenesis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Egenesis Comparisons
Competitors of eGenesis
eGenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, Korro Bio, Metagenomi, Prime Medicine and Scribe Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| domain | founded_year | HQ Location |
Genetic therapies for diseases are developed using prime editing technology.
|
|
| domain | founded_year | HQ Location |
A CRISPR-based gene-editing platform is developed for therapeutic applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Egenesis
Frequently Asked Questions about eGenesis
When was eGenesis founded?
eGenesis was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is eGenesis located?
eGenesis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of eGenesis?
Michael Curtis is the current CEO of eGenesis.
Is eGenesis a funded company?
eGenesis is a funded company, having raised a total of $481.42M across 6 funding rounds to date. The company's 1st funding round was a Series C of $125M, raised on Aug 22, 2016.
How many employees does eGenesis have?
As of Dec 31, 2022, the latest employee count at eGenesis is 94.
What does eGenesis do?
eGenesis was founded in 2015 and is based in Cambridge, United States. Operations focus on the biotechnology sector, where a gene transplantation platform is utilized to humanize pig cells for producing human-compatible organs. This technology relies on next-generation genome engineering and CRISPR tools. Organs grown in donor pigs are harvested for safe transplantation into human patients, addressing needs in organ transplantation.
Who are the top competitors of eGenesis?
eGenesis's top competitors include Tessera Therapeutics, Korro Bio and Beam Therapeutics.
What products or services does eGenesis offer?
eGenesis offers EGEN Platform and HuCo Organs.
How many acquisitions has eGenesis made?
eGenesis has made 1 acquisition, including ICBiotec.
Who are eGenesis's investors?
eGenesis has 27 investors. Key investors include Bayer, ARE, DaVita, Natco Pharma, and Khosla Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.